ArticleThe American journal of pathology1999
Analysis of E-cadherin in diffuse-type gastric cancer using a mutation-specific monoclonal antibody.
Article in The American journal of pathology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 72 citations in OpenAlex.
- Review
- TSNAD: an integrated software for cancer somatic mutation and tumour-specific neoantigen detection.Royal Society open science · 2017Article
- Kinetic Measurements Reveal Enhanced Protein-Protein Interactions at Intercellular Junctions.Scientific reports · 2016Article
- Quantification of mutant E-cadherin using bioimaging analysis of in situ fluorescence microscopy. A new approach to CDH1 missense variants.European journal of human genetics : EJHG · 2015Article
- Deregulation of the cell polarity protein Lethal giant larvae 2 (Lgl2) correlates with gastric cancer progression.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2014Article
- Cadherin point mutations alter cell sorting and modulate GTPase signaling.Journal of cell science · 2012Article
- Tissue organization by cadherin adhesion molecules: dynamic molecular and cellular mechanisms of morphogenetic regulation.Physiological reviews · 2011Review
- 177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.European journal of nuclear medicine and molecular imaging · 2011Article
- Differential gene expression triggered by highly cytotoxic alpha-emitter-immunoconjugates in gastric cancer cells.Investigational new drugs · 2010Article
- A case of multiple diffuse gastric carcinoma with regional expression of mutant E-cadherin.Virchows Archiv : an international journal of pathology · 2008Article
- Tumor specificity and in vivo targeting of an antibody against exon 9 deleted E-cadherin in gastric cancer.Journal of cancer research and clinical oncology · 2007Article
- 213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice.Cancer science · 2007Article
- Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and E-cadherin expression in gastric cancer.Journal of clinical pathology · 2007Article
- Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging.European journal of nuclear medicine and molecular imaging · 2007Article
- The histochemistry and cell biology vade mecum: a review of 2005-2006.Histochemistry and cell biology · 2006Review
- Expression and nuclear localization of Snail, an E-cadherin repressor, in adenocarcinomas of the upper gastrointestinal tract.Virchows Archiv : an international journal of pathology · 2006Article
- Early gastric cancer: concepts, diagnosis, and management.International journal of clinical oncology · 2005Review
- Recent progress in histochemistry and cell biology: the state of the art 2005.Histochemistry and cell biology · 2005Review
- Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death.European journal of nuclear medicine and molecular imaging · 2005Article
- CDH1 germline mutation in hereditary gastric carcinoma.World journal of gastroenterology · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In-frame deletions from the E-cadherin mRNA, coding for a homophilic cell adhesion molecule, are characteristic for diffuse-type gastric carcinomas. Using immunohistochemical analysis the mutant form cannot be distinguished from normal E-cadherin, making results difficult to interpret. In this study, a rat monoclonal antibody, designated E-cad delta 9-1, was generated against a peptide spanning the fusion junction region between exons 8 and 10. This new epitope is present in an E-cadherin variant that lacks exon 9 from the mRNA due to different splice-site gene mutations. Using Western blotting and immunohistochemistry of E-cadherin-transfected cells, we demonstrate that E-cad delta 9-1 specifically reacts with E-cadherin lacking exon 9 but not with the wild-type protein. No immunoreactivity was observed in 31 nontumorous and embryonal tissues analyzed. In gastric carcinoma specimens known to express mutant E-cadherin mRNA lacking exon 9, E-cad delta 9-1 targets exclusively tumor cells in routine formalin-fixed and paraffin-embedded material from biopsies, primary tumors, and lymph node metastases. In a retrospective series of 172 diffuse-type gastric carcinomas expressing E-cadherin, E-cad delta 9-1 reacted with 22 tumors (13%). This new tumor marker-monoclonal antibody system could open novel avenues for selective diagnosis and specific therapy of a subgroup of diffuse-type gastric cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.